Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025JCO Precision Oncology

Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHamdy A. AzimHEHagar ElghazawyKSKyrillus S. Shohdy

Discussion

Loading...

Member takes

Overview

Systematic review reveals brca mutation worsens OS and PFS in hormone receptor-positive breast cancer, indicating unique treatment challenges.

Key Points

  • BRCA mutation is linked to worse overall survival (OS) and progression-free survival (PFS) in hormone receptor-positive breast cancer.
  • Meta-analysis included 22 studies, totaling 34,960 patients with varying outcomes based on BRCA mutation status.
  • BRCA1/2 mutant patients showed significantly poorer prognosis compared to wild-type, especially when treated with endocrine therapy plus CDK4/6 inhibitors.
  • The findings suggest a unique resistance of BRCA2 mutants to therapy, emphasizing the need for targeted approaches in treatment.

Cite This Study

Azim et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d18e2https://doi.org/10.1200/po-24-00841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study2025
  2. 2Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancer2025
  3. 3Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis2025 · 4 citations
  4. 4Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety2025
  5. 5Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma2025